Sector News

Shire weighs Takeda's cash-sweetened $61.5B offer

April 24, 2018
Life sciences

The third time wasn’t the charm for Takeda in its attempts to swallow Shire—but the fourth time might be.

On Friday, the Dublin drugmaker said it had received a new offer from Japan’s largest pharma, comprising £26 per share in new Takeda shares and and £21 per share in cash—good for £47 per share total, or about £44 billion ($61.6 billion).

And unlike Takeda’s first three bids of £46.50, £45.50 and £44.00 per share, which Shire rejected, the company is actually considering this one.

“The board of Shire is considering its position with respect to the fourth proposal and will issue a further announcement in due course,” it said in a statement.

The news comes just one day after word that Shire had already shot down the trio of Takeda bids. Thursday also saw traditionally M&A-happy Allergan reveal that it had muscled its way into a spot at the dealmaking table, only to turn around and walk away a few hours later, to the market’s great relief.

Still, the flip-flop may have struck a little fear into Takeda, which doesn’t have a whole lot of room to keep raising its offer without going into serious debt. Several U.S. drugmakers, on the other hand, are rolling in potential dealmaking funds thanks to tax reform, and industry watchers have floated a few of them—think Pfizer, Amgen and AbbVie, which has already struck one deal for Shire—as potential suitors.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 25, 2023

UK regulator makes biggest changes in 20 years to speed up trials, attract global studies

Life sciences

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.

March 25, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

Life sciences

Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.

March 25, 2023

Sanofi’s Dupixent receives EC approval for atopic dermatitis

Life sciences

Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.

How can we help you?

We're easy to reach